Skip to content
Disclosery

Avoro Capital Advisors LLC

Follow

13F filer, CIK 1633313, NEW YORK, NY

Avoro Capital Advisors LLC reported $5,710,277,507 across 30 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 73.58% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-25-078127

Period
2025-06-30
Reported value
$5.71B
Holdings
30
Top 10 weight
73.58%
New
1
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
AKROnew+3,500,000$187M
MLTXadded+1,379,900$65.1M
QUREadded+1,450,000$20.2M
VERAadded+598,100$14.1M
ALKSadded+450,000$12.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BLUEPRINT MEDICINES CORPreduced-3,475,000-$445M
SRPTexited-2,674,835-$171M
UTHRreduced-305,000-$87.6M
INTRA-CELLULAR THERAPIES INCexited-625,000-$82.5M
MDGLreduced-147,222-$44.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001104659-25-078127, largest first. % of portfolio is the value over $5,710,277,507, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,988,888 shares; 2024Q4: 5,103,055 shares; 2025Q1: 5,218,000 shares; 2025Q2: 4,980,000 shares 4,980,000$860M15.05%-238,000Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,858,888 shares; 2024Q4: 2,760,300 shares; 2025Q1: 2,675,000 shares; 2025Q2: 2,370,000 shares 2,370,000$681M11.93%-305,000Timeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,238,467 shares; 2024Q4: 1,238,467 shares; 2025Q1: 1,235,177 shares; 2025Q2: 1,175,000 shares 1,175,000$648M11.34%-60,177Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,029,000 shares; 2024Q4: 2,029,000 shares; 2025Q1: 2,022,222 shares; 2025Q2: 1,875,000 shares 1,875,000$567M9.94%-147,222Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,622,222 shares; 2024Q4: 2,628,822 shares; 2025Q1: 2,731,000 shares; 2025Q2: 2,660,000 shares 2,660,000$366M6.4%-71,000Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,500,000 shares; 2024Q4: 5,150,000 shares; 2025Q1: 6,460,000 shares; 2025Q2: 6,555,555 shares 6,555,555$286M5.01%+95,555Timeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,111,111 shares; 2024Q4: 12,222,222 shares; 2025Q1: 12,222,222 shares; 2025Q2: 12,222,222 shares 12,222,222$212M3.71%0Timeline
RNAMAVIDITY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,875,000 shares; 2024Q4: 7,500,000 shares; 2025Q1: 7,625,000 shares; 2025Q2: 7,050,000 shares 7,050,000$200M3.51%-575,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,770,100 shares; 2024Q4: 2,770,100 shares; 2025Q1: 2,770,100 shares; 2025Q2: 4,150,000 shares 4,150,000$196M3.43%+1,379,900Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,500,000 shares 3,500,000$187M3.27%newTimeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,181,000 shares; 2024Q4: 2,525,000 shares; 2025Q1: 2,525,000 shares; 2025Q2: 2,050,000 shares 2,050,000$172M3.01%-475,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,666,666 shares; 2024Q4: 5,666,666 shares; 2025Q1: 5,741,666 shares; 2025Q2: 5,400,000 shares 5,400,000$169M2.96%-341,666Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,888,888 shares; 2024Q4: 11,111,111 shares; 2025Q1: 11,111,111 shares; 2025Q2: 10,600,000 shares 10,600,000$167M2.93%-511,111Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,355,000 shares; 2024Q4: 2,125,000 shares; 2025Q1: 3,000,000 shares; 2025Q2: 3,155,555 shares 3,155,555$166M2.91%+155,555
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,309,590 shares; 2024Q4: 5,610,000 shares; 2025Q1: 5,701,900 shares; 2025Q2: 6,300,000 shares 6,300,000$148M2.6%+598,100Timeline
FOLDAMICUS THERAPEUTICQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 23,175,000 shares; 2024Q4: 23,175,000 shares; 2025Q1: 20,500,000 shares; 2025Q2: 18,000,000 shares 18,000,000$103M1.81%-2,500,000Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,450,000 shares; 2025Q1: 2,450,000 shares; 2025Q2: 2,900,000 shares 2,900,000$83M1.45%+450,000Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,060,000 shares; 2024Q4: 8,060,000 shares; 2025Q1: 8,060,000 shares; 2025Q2: 7,400,000 shares 7,400,000$68.7M1.2%-660,000Timeline
89BIO INC89BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 4,100,000 shares; 2025Q1: 6,350,000 shares; 2025Q2: 6,750,000 shares 6,750,000$66.3M1.16%+400,000
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,050,000 shares; 2025Q2: 5,000,000 shares 5,000,000$65.7M1.15%+950,000Timeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,175,000 shares; 2025Q1: 2,175,000 shares; 2025Q2: 3,625,000 shares 3,625,000$50.5M0.88%+1,450,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,650,000 shares; 2024Q4: 19,999,999 shares; 2025Q1: 19,999,999 shares; 2025Q2: 21,700,000 shares 21,700,000$50.1M0.88%+1,700,001Timeline
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,185,000 shares; 2025Q1: 3,850,000 shares; 2025Q2: 375,000 shares 375,000$48.1M0.84%-3,475,000
Tourmaline Bio IncTourmaline Bio IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,222,222 shares; 2024Q4: 2,222,222 shares; 2025Q1: 2,425,000 shares; 2025Q2: 2,555,555 shares 2,555,555$40.9M0.72%+130,555
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,865,000 shares; 2024Q4: 11,865,000 shares; 2025Q1: 8,700,000 shares; 2025Q2: 4,500,000 shares 4,500,000$40.3M0.71%-4,200,000Timeline
MNKDMANNKIND CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,750,000 shares; 2024Q4: 8,750,000 shares; 2025Q1: 8,750,000 shares; 2025Q2: 5,850,000 shares 5,850,000$21.9M0.38%-2,900,000Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,790,236 shares; 2024Q4: 4,345,000 shares; 2025Q1: 4,645,548 shares; 2025Q2: 3,725,000 shares 3,725,000$16.8M0.29%-920,548Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,110,000 shares; 2025Q1: 1,337,500 shares; 2025Q2: 1,237,500 shares 1,237,500$13.1M0.23%-100,000Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 830,000 shares; 2024Q4: 830,000 shares; 2025Q1: 830,000 shares; 2025Q2: 330,000 shares 330,000$12M0.21%-500,000Timeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,849,402 shares; 2024Q4: 2,849,402 shares; 2025Q1: 2,849,402 shares; 2025Q2: 2,849,402 shares 2,849,402$5.33M0.09%0Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SRPTSAREPTA THERAPEUTICS INC2,674,835$171Mshares
INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INC625,000$82.5Mshares
PCVXVAXCYTE INC1,000,000$37.8Mshares
AUTLAUTOLUS THERAPEUTICS LTD9,910,642$15.4Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-25-078127 base2025-08-14acceptance time not in the bulk data set